Compare StocksABBV vs TXN

AbbVie Inc. (ABBV) vs Texas Instruments Incorporated (TXN): Which Is the Better Buy in 2026?

As of 2026-06-19, ABBV is overvalued at $216, with a DCF intrinsic value of $160 and a margin of safety of -35%. TXN is overvalued at $323, with an intrinsic value of $283 and a margin of safety of -14%. Of the two, TXN has the wider margin of safety.

ABBV
AbbVie Inc.
$216.49
VS
TXN
Texas Instruments Incorporated
$322.86

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
TXN
  • Texas Instruments Incorporated has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • Return on equity has consistently exceeded 20% over 4 years, indicating efficient use of shareholder capital.
  • Altman Z-Score of 8.73 indicates very low bankruptcy risk — the company is firmly in the safe zone.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • FCF yield of 5.4% suggests reasonable valuation assuming continued moderate growth.
  • Trailing P/E of 105.6x is 69% above the historical average of 62.3x — the stock trades at a premium to its own history.
TXN
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • FCF yield of 0.9% is below 3%, meaning the market is pricing in substantial future growth to justify the current price.
  • Trailing P/E of 55.3x is 104% above the historical average of 27.1x — the stock trades at a premium to its own history.

Key Valuation Metrics

Learn more →
ABBV
TXN
Valuation
$20.81B
Free Cash Flow
$2.60B
5.44%
FCF Yield
0.89%
105.60
Trailing P/E
55.28
13.32
Forward P/E
34.27
Quality & Moat
21.89%
ROIC
17.87%
N/A
ROE
32.35%
72.03%
Gross Margin
57.32%
0.61
PEG Ratio
1.46
Balance Sheet Safety
N/A
Net Debt / Equity
0.53
N/A
Interest Coverage
N/A
2.12
Net Debt / EBITDA
1.03
3.11%
Dividend Yield
1.84%
ABBV: 7Ties: 1TXN: 2
ABBVTXN

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

TXN

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
TXN
$3.91
created per $1 retained over 3 years
Exceptional Value Creator
Σ Retained
$1.96B
Δ Market Cap
+$7.67B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
35.3% Overvalued
Price is 35.3% above estimated fair value
Current Price: $216.49
Fair Value: $160.05
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
TXN
31.8% Overvalued
Price is 31.8% above estimated fair value
Current Price: $322.86
Fair Value: $245.00
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

What growth rate is the market pricing in at $216?

+17.1%
Market-Implied Owner Earnings Growth
Standard FCF implies +8.7%

The market implies +17.1% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +8.7%, reflecting heavy growth investment.

TXN

What growth rate is the market pricing in at $323?

+22.8%
Market-Implied Owner Earnings Growth
Standard FCF implies +32.1%

The market implies +22.8% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +32.1%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
TXN
48/100
Narrow Moat
70+ Wide · 40-69 Narrow · <40 None

Narrow moat with roic consistency as the key competitive advantage. Improving reinvestment efficiency would strengthen the moat.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
TXN
-2.67
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
No. of Institutional Holders5,106
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
TXN
Insiders 0.3%Institutions 92.6%Retail & Other 7.1%
No. of Institutional Holders3,235
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
TXN
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
0
Sells (3M)
5
Sells (12M)
Total value (12M): $21.79M
PURDUE DAVID R.
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
GONZALEZ RICHARD A
Officer and Director
$12.40M
@ $186.52 · 2024-08-05
GONZALEZ RICHARD A
Officer and Director
$49.50M
@ $175.00 · 2024-07-17
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
TXN
18
Sells (3M)
28
Sells (12M)
Total value (12M): $113.32M
CRAIGHEAD MARTIN S
Director
$3.20M
@ $320.43 · 2026-05-28
LIZARDI RAFAEL R
Chief Financial Officer
$14.71M
@ $308.10 · 2026-05-14
BAHAI AHMAD
Officer
$1.55M
@ $309.13 · 2026-05-14
COX CARRIE SMITH
Director
$2.71M
@ $306.41 · 2026-05-13
LEONARD SHANON J
Officer
$1.47M
@ $295.22 · 2026-05-11
ILAN HAVIV
Chief Executive Officer
$5.61M
@ $280.32 · 2026-05-04
KNECHT JULIE C.
Officer
$2.77M
@ $278.70 · 2026-05-01
GARY MARK
Officer
$3.82M
@ $279.25 · 2026-04-30
ROBERTS MARK T
Officer
$7.87M
@ $280.34 · 2026-04-30
YUNUS MOHAMMAD
Officer
$13.82M
@ $270.44 · 2026-04-29
KANE KATHARINE
General Counsel
$1.66M
@ $270.41 · 2026-04-27
BAHAI AHMAD
Officer
$982,359
@ $268.40 · 2026-04-27
RON AMICHAI
Officer
$5.00M
@ $272.43 · 2026-04-24
WITZSCHE CHRISTINE
Officer
$998,771
@ $275.52 · 2026-04-24
LEONARD SHANON J
Officer
$5.06M
@ $277.95 · 2026-04-24
BLUEDORN TODD M
Director
$1.18M
@ $274.25 · 2026-04-24
PATSLEY PAMELA H
Director
$1.19M
@ $276.11 · 2026-04-24
LIZARDI RAFAEL R
Chief Financial Officer
$11.12M
@ $274.23 · 2026-04-24
KOZANIAN HAGOP H
Officer
$1.55M
@ $225.95 · 2026-02-17
GARY MARK
Officer
$5.24M
@ $226.00 · 2026-02-11
LIZARDI RAFAEL R
Chief Financial Officer
$15.88M
@ $221.73 · 2026-02-11
BAHAI AHMAD
Officer
$1.50M
@ $230.79 · 2026-02-11
ROBERTS MARK T
Officer
$986,604
@ $221.16 · 2026-02-09
BLINN MARK A
Director
$696,647
@ $221.58 · 2026-02-05
BAHAI AHMAD
Officer
$670,387
@ $223.46 · 2026-02-05
KIRK RONALD
Director
$1.62M
@ $162.33 · 2025-11-24
WITZSCHE CHRISTINE
Officer
$164,306
@ $164.31 · 2025-11-13
BAHAI AHMAD
Officer
$308,030
@ $205.35 · 2025-08-25
TEMPLETON RICHARD K
Chairman of the Board
$19.85M
@ $195.41 · 2025-02-28
TEMPLETON RICHARD K
Chairman of the Board
$38.65M
@ $199.20 · 2025-02-26
CLARK JANET F
Director
$1.23M
@ $203.62 · 2025-02-24
TEMPLETON RICHARD K
Chairman of the Board
$39.32M
@ $202.70 · 2025-02-24
BLINN MARK A
Director
$1.17M
@ $189.89 · 2025-02-19
LEONARD SHANON J
Officer
$401,241
@ $186.62 · 2025-02-18
BLINN MARK A
Director
$106,617
@ $180.71 · 2025-02-04
KIRK RONALD
Director
$2.14M
@ $203.33 · 2024-11-25
GARY MARK
Officer
$3.49M
@ $219.82 · 2024-11-08
ILAN HAVIV
Chief Executive Officer
$2.88M
@ $219.30 · 2024-11-08
YUNUS MOHAMMAD
Officer
$1.81M
@ $216.94 · 2024-11-07
LIZARDI RAFAEL R
Chief Financial Officer
$10.19M
@ $217.16 · 2024-11-07
BAHAI AHMAD
Officer
$472,514
@ $217.25 · 2024-11-07
GARY MARK
Officer
$940,296
@ $214.83 · 2024-11-06
WITZSCHE CHRISTINE
Officer
$27,941
@ $211.67 · 2024-11-06
ILAN HAVIV
Chief Executive Officer
$5.29M
@ $211.50 · 2024-11-06
SANCHEZ ROBERT E
Director
$2.09M
@ $208.80 · 2024-10-25
RON AMICHAI
Officer
$2.76M
@ $213.72 · 2024-08-29
GARY MARK
Officer
$3.22M
@ $212.63 · 2024-08-29
ROBERTS MARK T
Officer
$1.00M
@ $213.08 · 2024-08-29
PATSLEY PAMELA H
Director
$1.29M
@ $212.43 · 2024-08-29
BAHAI AHMAD
Officer
$892,427
@ $209.98 · 2024-08-27
YUNUS MOHAMMAD
Officer
$789,215
@ $208.90 · 2024-08-26
ILAN HAVIV
Chief Executive Officer
$251,324
@ $209.44 · 2024-08-26
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😐Neutral(56/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
TXN
FearGreed
😏Greed(63/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (56)
TXN
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (63)
View ABBV Full AnalysisView TXN Full Analysis

Frequently Asked Questions: ABBV vs TXN

Is AbbVie Inc. or Texas Instruments Incorporated more undervalued in 2026?

Based on our discounted cash flow model, TXN trades at a -13.9% margin of safety (intrinsic value $283 vs. price $323), compared to ABBV's -35.3% margin of safety (intrinsic $160 vs. $216).

Which stock has a wider economic moat, AbbVie Inc. or Texas Instruments Incorporated?

ABBV scores 82/100 (Wide moat), while TXN scores 48/100 (Narrow moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. TXN scores 8.7 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which company has better free cash flow, AbbVie Inc. or Texas Instruments Incorporated?

AbbVie Inc. (ABBV) generates a 5.4% free cash flow yield, compared to Texas Instruments Incorporated's 0.9%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, AbbVie Inc. or Texas Instruments Incorporated?

ABBV earns 21.9% ROIC versus TXN's 17.9%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or Texas Instruments Incorporated's?

ABBV's dividend earns a safety score of 39/100 (Unsafe), compared to TXN's 34/100 (Unsafe). ABBV has raised its dividend for 3 consecutive years.

ABBV vs TXN: Which Is the Better Buy in 2026? | SafetyMargin.io